A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatocellular carcinoma (HCC) can develop in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) levels. Therefore, methods that can stratify an individual’s HCC risk are needed. Methods: A simple HCC risk score was developed from 971 patients with CHB who had elevated hepatitis B virus DNA levels (>2,000 IU/mL) with normal or mildly elevated ALT levels (<80 U/L). The score was validated from an independent cohort of 507 patients. Results: A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5 years for the lowest and highest risk scores. The D2AS score had high area under the receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years (0.895/0.884). The calculated AUROCs to predict the development of HCC at 3/5 years were 0.889/0.876 in the validation cohort, with 5-year HCC incidence rates ranging from 0% to 13.8% at 5 years for the lowest and highest risk scores. Conclusions: The D2AS risk score can play a valuable role in risk stratification and may be useful for guiding clinical decisions for enhanced surveillance or treatment to reduce the HCC risk in CHB patients with normal or mildly elevated ALT levels.
Abstract
Background/Aims: Hepatocellular carcinoma (HCC) can develop in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) levels. Therefore, methods that can stratify an individual’s HCC risk are needed. Methods: A simple HCC risk score was developed from 971 patients with CHB who had elevated hepatitis B virus DNA levels (>2,000 IU/mL) with normal or mildly elevated ALT levels (<80 U/L). The score was validated from an independent cohort of 507 patients. Results: A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5 years for the lowest and highest risk scores. The D2AS score had high area under the receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years (0.895/0.884). The calculated AUROCs to predict the development of HCC at 3/5 years were 0.889/0.876 in the validation cohort, with 5-year HCC incidence rates ranging from 0% to 13.8% at 5 years for the lowest and highest risk scores. Conclusions: The D2AS risk score can play a valuable role in risk stratification and may be useful for guiding clinical decisions for enhanced surveillance or treatment to reduce the HCC risk in CHB patients with normal or mildly elevated ALT levels.
참고문헌 (27)
- Trépo C, "Hepatitis B virus infection", Lancet, 384, pp.2053~2063 (2014)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Yim HJ, "Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005", Hepatology, 43(2 Suppl 1), pp.S173~S181 (2006)
- Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
- Pratt DS, "Evaluation of abnormal liver-enzyme results in asymptomatic patients", N Engl J Med, 342, pp.1266~1271 (2000)
- Kumar M, "Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT", Gastroenterology, 134, pp.1376~1384 (2008)
- Lai M, "The clinical significance of persistently normal ALT in chronic hepatitis B infection", J Hepatol, 47, pp.760~767 (2007)
- Tong MJ, "Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States", Hepatology, 48, pp.1070~1078 (2008)
- Yang JD, "Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.64~70 (2011)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Park HN, "Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease", Liver Int, 32, pp.937~944 (2012)
- Chao DT, "Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU", L and significant hepatic fibrosis, 2014, pp.39, 349~358
- Kumada T, "Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values", J Med Virol, 82, pp.539~545 (2010)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
- Clark TG, "Survival analysis part IV: further concepts and methods in survival analysis", Br J Cancer, 89, pp.781~786 (2003)
- Prati D, "Updated definitions of healthy ranges for serum alanine aminotransferase levels", Ann Intern Med, 137, pp.1~10 (2002)
- Kang HS, "Healthy range for serum ALT and the clinical significance of “unhealthy” normal ALT levels in the Korean population", J Gastroenterol Hepatol, 26, pp.292~299 (2011)
- Lee JK, "Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology", Hepatology, 51, pp.1577~1583 (2010)
- Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
- Jung KS, "Validation of hepatitis B virusrelated hepatocellular carcinoma prediction models in the era of antiviral therapy", Hepatology, 62, pp.1757~1766 (2015)